A Boost for Cervical Cancer Screening
Droplet digital PCR + HPV ccfDNA assay = diagnostic at low cost, with high specificity
At a Glance
- Cervical cancer is the fourth most common cancer in women, causing 270,000 global deaths in 2015
- The existing test for human papillomavirus (HPV) – a key risk factor of cervical cancer – lacks specificity
- A combination of droplet digital PCR and a circulating cell-free HPV DNA assay offers higher specificity for the cancer
- Studies have shown a 100 percent success rate in identifying and genotyping HPV-positive with recurrent metastatic cervical cancer cases; the ddPCR method is undergoing clinical trials for patient selection for T-cell immunotherapies
Despite a declining incidence rate in the US, cervical cancer remains the fourth most common cancer in women worldwide, causing 270,000 deaths in 2015, according to the World Health Organization. High-risk, persistent HPV infections are often a precursor to the disease, with about 0.8 percent of patients developing cancer over 10 to 30 years. The current HPV test with Pap samples, although very sensitive, can be relatively nonspecific and requires extensive follow-up testing for high-risk, HPV-positive patients. To tackle that problem, we and our colleagues at the National Cancer Institute (NCI) decided to create a more specific alternative by developing a blood-based HPV circulating cell-free DNA (ccfDNA) assay (1) – a test we believe would be a potentially valuable resource for the early detection of cervical cancer.
Our involvement in cervical cancers came about thanks to two main driving factors. First of all, there is a significant need for clinical biomarkers for the development of novel immunotherapies, including checkpoint antibody-based and T-cell based therapies (both investigational therapies originally invented at NCI). Specifically, there is an immediate need to select patients based on their HPV genotype for experimental T-cell therapies. Second, we recognized the real potential of using circulating cell-free HPV DNA for patient monitoring; the high copy numbers of virus genome per cancer cell and the lack thereof in normal cells led us to consider the use of such an assay for treatment assessment and recurrence evaluation.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine